Additionally, apart from anti-cancer activity which is a new experimental therapeutic target for cancer, the PPAR-γ agonist activity could be important in providing a pharmacological basis of its use in diabetes, wherein PPAR-γ agonists are clinically used for the management. The gene discussed is PPARG; the disease is diabetes mellitus.